Hector P.
- Country
- Spain
- Department
- Digestivo
Research Overview
- Evaluation of Safety, Engraftment, and Initial Clinical Activity of MB310 in Patients with Active Mild to Moderate Ulcerative Colitis: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study
- Phase 2 Adaptive Dose-Ranging Study of Eltrekibart and Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis
Data & Insights
Has run more than one trial at 4 of 124 partner sites.
Specializations
Inflammatory Bowel Disease
Specializes in the investigation of novel therapeutic approaches for Ulcerative Colitis, with particular focus on innovative treatment modalities for patients with varying disease severity levels.
- Moderate to Severe UC Management
- Mild to Moderate UC Interventions
- Immunomodulatory Therapies
Explores combination therapy approaches and investigates the potential of new biological agents in achieving clinical remission for UC patients.
Clinical Therapeutics
Focuses on evaluating novel biological treatments and their mechanisms of action in inflammatory bowel conditions, particularly investigating targeted therapies for gastrointestinal inflammation.
- Biological Agent Assessment
- Treatment Response Evaluation
- Clinical Remission Strategies
Investigates both monotherapy and combination treatment approaches to optimize therapeutic outcomes in inflammatory bowel disease.
Gastrointestinal Medicine
Conducts research in advanced therapeutic solutions for inflammatory bowel conditions, with emphasis on developing personalized treatment approaches for diverse patient populations.
- Disease Activity Assessment
- Treatment Safety Profiles
- Clinical Response Monitoring
Specializes in evaluating novel therapeutic compounds and their effectiveness in treating inflammatory bowel conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.